续新兵对财联社记者表示，上半年公司营收有所下滑是由于同期销售情况较好，基数偏大造成的。2024上半年，大输液、小容量注射剂销售趋于平稳，与去年同期相比，营收略有减少，造成了上半年公司总营收的下滑，预计下半年的销售情况整体趋于平稳。① At the performance meeting, Chen Xin Pharmaceutical's director, Xu Xinbing, explained the company's gross profit margin and decline in revenue in the first half of the year; ② Xu Xinbing said that the sales volume of the four H1 varieties that the company won the bid for in the eighth batch increased significantly year-on-year; ③ The company's chairman Du Zhenxin introduced the company's generic drug and innovative drug development.
Financial Services Association, September 9 (Reporter He Fan) At the semi-annual results briefing held today, Chen Xin Pharmaceutical (603367.SH) Director Xu Xinbing explained the decline in the company's revenue and gross margin in the first half of the year. At the same time, it was revealed that the sales volume of the four H1 varieties that won the bid by the company in the eighth batch increased significantly year-on-year. In addition, Du Zhenxin, chairman of Chen Xin Pharmaceutical, gave an introduction to the company's generic drug and innovative drug research and development.
According to the interim report, in the first half of this year, Chenxin Pharmaceutical achieved operating income of 2.071 billion yuan, a year-on-year decrease of 6.72%, and net profit to mother of 0.27 billion yuan, an increase of 2.33% over the previous year. Specifically for each business segment, the company's main business revenue for large infusions was 0.907 billion yuan, a year-on-year decrease of 13.62%, and revenue for small-volume injections was 0.628 billion yuan, a decrease of 7.1% over the previous year.
Xu Xinbing told the Financial Federation reporter that the decline in the company's revenue in the first half of the year was due to good sales conditions and a large base during the same period. In the first half of 2024, sales of large infusions and small volume injections stabilized. Compared with the same period last year, revenue declined slightly, causing the company's total revenue to decline in the first half of the year. The overall sales situation is expected to stabilize in the second half of the year.
In terms of gross margin, in the first half of this year, the company's overall gross margin was 57.68%, compared to 55.32% in the same period last year, an increase of 2.36 percentage points over the previous year.
In the eighth batch of nationwide collection held last year, Chenxin Pharmaceutical won the bid for all four varieties: methylcobalamin injection (1ml: 0.5mg), alanyl glutamine injection (50ml: 10g), metronidazole sodium chloride injection (100ml: 0.5g), and enoxaparin sodium injection (0.4ml: 4000 axAIU).
At the results meeting, a reporter from the Financial Services Association asked the company's management about the sales situation of the above drugs. Xu Xinbing replied that sales revenue for the four varieties in the first half of the year was 54.997 million yuan, an increase over the previous year, and sales volume increased significantly compared to the same period last year.
In terms of research and development, Du Zhenxin, chairman of Chenxin Pharmaceutical, explained that the company's new drug-resistant tuberculosis drug project is currently undergoing phase III clinical trials; the new anti-influenza drug project has completed phase II clinical trials and is preparing to enter phase III clinical trials.
Judging from the semi-annual report, Chenxin Pharmaceutical's R&D expenses reached 0.179 billion yuan, an increase of 15.25% over the previous year. In addition to innovative drugs, in terms of generic drugs, the company obtained production approvals for 10 varieties, including lurasidone hydrochloride tablets, and obtained registration numbers for 2 APIs, etc.
